Browse by category

Eli Lilly and Company has announced an agreement with the US government to expand access to its obesity medicines and reduce patient costs. In 2020, Lilly partnered with the Trump Administration on a pilot programme that paved the way for Lilly to be the first company to cap out-of-pocket insulin costs at $35 per month. Lilly will now improve access to nearly 40 million Americans living with obesity on government insurance programmes and millions more who pay out-of-pocket. U

Results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of orforglipron, an investigational oral glucagon-like...

Eli Lilly and Company has announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational...

The topline Phase 3 results from Eli Lilly ACHIEVE-1 study, evaluating the safety and efficacy of orforglipron compared to placebo in...

The American Diabetes Association (ADA) has announced a new suite of resources to support improved care for those living with obesity....

The FDA has approved Eli Lilly and Company’s Zepbound (tirzepatide) as the first and only prescription medicine for adults with...

Laekna Therapeutics has entered a clinical collaboration with Eli Lilly to accelerate the development of LAE102, a novel Activin Receptor...

Eli Lilly and Company has announced a strategic collaboration with the UK’s Department of Health and Social Care (DHSC), Department for...

Eli Lilly and Company has announced Zepbound (tirzepatide) 2.5mg and 5mg single-dose vials are available for self-pay for patients with...

The World Health Organization (WHO) has issued a medical product alert on falsified semaglutides, the type of medicines that are used for...